Aaron M. Kipp

Aaron M. Kipp

Auto-generated profile, based on publicly available information

Aaron M. Kipp

Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2014 in AIDS and Behavior
Verified
Journal Article
Closed access
PDF file
CVCarla Valenzuela
Carla Valenzuela
CUCesar Ugarte-Gil
Cesar Ugarte-Gil
JPJorge Paz
Jorge Paz
JEJuan Echevarria
Juan Echevarria
EGEduardo Gotuzzo
Eduardo Gotuzzo
AKAaron M. Kipp
Aaron M. Kipp

23 January 2021 in Social Science & Medicine
Verified
Journal Article
Closed access
JDJoseph Daniels
Joseph Daniels
AMAndrew Medina-Marino
Andrew Medina-Marino
KGKatherine Glockner
Katherine Glockner
EGEmily Grew
Emily Grew
NNNondumiso Ngcelwane
Nondumiso Ngcelwane
AKAaron Kipp
Aaron Kipp

30 August 2011 in BMC Public Health
Verified
Journal Article
Open access
PDF file
AKAaron M Kipp
Aaron M Kipp
PPPetchawan Pungrassami
Petchawan Pungrassami
KNKittikorn Nilmanat
Kittikorn Nilmanat
SSSohini Sengupta
Sohini Sengupta
CPCharles Poole
Charles Poole
ARAnnelies Van Rie
Annelies Van Rie
Tuberculosis (TB) remains one of the most important infectious diseases worldwide. A comprehensive approach towards disease control that addresses social factors including stigma is now advocated. Patients with TB report fears of isolation and rejection that may lead to delays in seeking care and could affect treatment adherence. Qualitative studies have identified socio-demographic, TB knowledge, and clinical determinants of TB stigma, but only one prior study has quantified these associations using formally developed and validated stigma scales. The purpose of this study was to measure TB stigma and identify factors associated with TB stigma among patients and healthy community members.

8 January 2016 in BMJ Open
Verified
Journal Article
Open access
PDF file
AKAaron M Kipp
Aaron M Kipp
MBMeridith Blevins
Meridith Blevins
CHConnie A Haley
Connie A Haley
KMKasonde Mwinga
Kasonde Mwinga
PHPhanuel Habimana
Phanuel Habimana
Sten H. VermundSten H. Vermund
Sten H. Vermund
Objective Inadequate overall progress has been made towards the 4th Millennium Development Goal of reducing under-five mortality rates by two-thirds between 1990 and 2015. Progress has been variable across African countries. We examined health, economic and social factors potentially associated with reductions in under-five mortality (U5M) from 2000 to 2013. Setting Ecological analysis using publicly available data from the 46 nations within the WHO African Region. Outcome measures We assessed the annual rate of change (ARC) of 70 different factors and their association with the annual rate of reduction (ARR) of U5M rates using robust linear regression models. Results Most factors improved over the study period for most countries, with the largest increases seen for economic or technological development and external financing factors. The median (IQR) U5M ARR was 3.6% (2.8 to 5.1%). Only 4 of 70 factors demonstrated a strong and significant association with U5M ARRs, adjusting for potential confounders. Higher ARRs were associated with more rapidly increasing coverage of seeking treatment for acute respiratory infection (β=0.22 (ie, a 1% increase in the ARC was associated with a 0.22% increase in ARR); 90% CI 0.09 to 0.35; p=0.01), increasing health expenditure relative to gross domestic product (β=0.26; 95% CI 0.11 to 0.41; p=0.02), increasing fertility rate (β=0.54; 95% CI 0.07 to 1.02; p=0.07) and decreasing maternal mortality ratio (β=−0.47; 95% CI −0.69 to −0.24; p<0.01). The majority of factors showed no association or raised validity concerns due to missing data from a large number of countries. Conclusions Improvements in sociodemographic, maternal health and governance and financing factors were more likely associated with U5M ARR. These underscore the essential role of contextual factors facilitating child health interventions and services. Surveillance of these factors could help monitor which countries need additional support in reducing U5M.

1 November 2011 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
AKA.M. Kipp
A.M. Kipp
PPP. Pungrassami
P. Pungrassami
PSP.W. Stewart
P.W. Stewart
VCV. Chongsuvivatwong
V. Chongsuvivatwong
RSR.P. Strauss
R.P. Strauss
ARA. Van Rie
A. Van Rie
BACKGROUND: Adherence to tuberculosis (TB) treatment is important for TB control. The effect of stigma on adherence has not been well quantified. OBJECTIVE: To identify the effects of TB and acquired immune-deficiency syndrome (AIDS) stigma on missed doses during TB treatment. DESIGN: Validated TB and AIDS stigma scales assessing perceived and experienced/felt stigma were administered in a prospective cohort of 459 TB patients at TB treatment initiation and after 2 months. Repeated measures and multivariable models estimated the effects of stigma on the rate of missed doses. RESULTS: Fifty-six per cent of patients missed no doses, and associations between stigma and missed doses were minimal. Heterogeneity of effects was observed, how- ever, with higher experienced and felt TB stigma increasing missed doses among women (adjusted RR 1.22, 95%CI 1.10–1.34) and human immunodeficiency virus (HIV) co-infected patients (aRR 1.39, 95%CI 1.13–1.72). Experienced and felt AIDS stigma also increased missed doses among HIV co-infected patients (aRR 1.43, 95%CI 1.31–1.56). CONCLUSION: Stigma has a minimal effect in this population with good adherence. Among women and HIV co-infected patients, however, experienced and felt stigma, and not perceived stigma, increased the rate of missed doses. Further research is needed to determine if stigma or coping interventions among these subgroups would improve adherence.

22 October 2020 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
DBDana Bresenham
Dana Bresenham
AKAaron M. Kipp
Aaron M. Kipp
AMAndrew Medina-Marino
Andrew Medina-Marino
Background: South Africa has one of the world’s worst tuberculosis (TB) (520 per 100 000 population) and TB-human immunodeficiency virus (HIV) epidemics (~ 56% TB/HIV co-infected). While individual- and system-level factors influencing progression along the TB cascade have been identified, the impact of stigma is underexplored and underappreciated. We conducted an exploratory study to 1) describe differences in perceived community-level TB stigma among community members, TB presumptives, and TB patients, and 2) identify factors associated with TB stigma levels among these groups. Methods: A cross sectional study was conducted in November 2017 at public health care facilities in Buffalo City Metro (BCM) and Zululand health districts, South Africa. Community members, TB presumptives, and TB patients were recruited. Data were collected on sociodemographic characteristics, TB knowledge, health and clinical history, social support, and both HIV and TB stigma. A validated scale assessing perceived community TB stigma was used. Univariate and multivariate linear regression models were used to describe differences in perceived community TB stigma by participant type and to identify factors associated with TB stigma. Results: We enrolled 397 participants. On a scale of zero to 24, the mean stigma score for TB presumptives (14.7 ± 4.4) was statistically higher than community members (13.6 ± 4.8) and TB patients (13.3 ± 5.1). Community members from Zululand (β = 5.73; 95% CI 2.19, 9.72) had higher TB stigma compared to those from BCM. Previously having TB (β = − 2.19; 95% CI − 4.37, 0.0064) was associated with reduced TB stigma among community members. Understanding the relationship between HIV and TB disease (β = 2.48; 95% CI 0.020, 4.94), and having low social support (β = − 0.077; 95% CI − 0.14, 0.010) were associated with increased TB stigma among TB presumptives. Among TB Patients, identifying as Black African (β = − 2.90; 95% CI − 4.74, − 1.04) and knowing the correct causes of TB (β = − 2.93; 95% CI − 4.92, − 0.94) were associated with decreased TB stigma, while understanding the relationship between HIV and TB disease (β = 2.48; 95% CI 1.05, 3.90) and higher HIV stigma (β = 0.32; 95% CI 0.21, 0.42) were associated with increased TB stigma. Conclusions: TB stigma interventions should be developed for TB presumptives, as stigma may increase initial-loss-to-follow up. Given that stigma may be driven by numerous factors throughout the TB cascade, adaptive stigma reduction interventions may be required.